Diagnostics Pipeline: Cizzle Bio Introduces Test for Earlier Lung Cancer Detection
The CIZ1B biomarker blood-based assay has 95% sensitivity for detecting earliest stage of the cancer
The CIZ1B biomarker blood-based assay has 95% sensitivity for detecting earliest stage of the cancer
From – Diagnostic Testing & Emerging Technologies
Epigenetic changes, measured by DNA methylation, may be a predictor of biological age, according to a study published in…
From – Diagnostic Testing & Emerging Technologies
Summer may be over but the fight against the mosquito-borne virus, Zika, continues in earnest. Locally-mosquito-transmitted cases in…
From – Diagnostic Testing & Emerging Technologies
The U.S. Food and Drug Administration (FDA) recently approved the first rapid molecular test for detection of antibiotic resistance directly from…